Psoriatic Arthritis
Upadacitinib, deucravacitinib ‘the top two’ small molecules for psoriatic arthritis
Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal Disease.
VIDEO: JAK inhibitors in dermatology effective, ‘safer than we could have ever hoped for’
MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.
Physicians may overlook ‘deep sense of vulnerability’ in patients with psoriatic arthritis
Uncertainty about future care and life impacts were among the top concerns for patients with psoriatic arthritis, but not for physicians, who highly prioritized individual symptoms, according to data published in ACR Open Rheumatology.
‘We applaud CMS’: Two more rheumatology drugs bound for Medicare price negotiation
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — a move applauded by experts as they await the impact of the first-round of discounts anticipated next year.
No cardiovascular risk differences found between biologic treatments for psoriatic disease
A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse cardiovascular and venous thromboembolic events compared with those treated with tumor necrosis factor inhibitors.
Direct switch from TNFi to tofacitinib shows ‘acceptable’ safety in psoriatic arthritis
For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.
Celltrion's Steqeyma nabs FDA approval as seventh Stelara biosimilar
The FDA has approved the Stelara biosimilar Steqeyma for the treatment of adults and children with plaque psoriasis and psoriatic arthritis and adults with Crohn’s disease and ulcerative colitis, Celltrion announced in a press release.
Withholding methotrexate after zoster vaccine ‘shows promise’ in raising humoral response
WASHINGTON — Patients with autoimmune rheumatic diseases who withhold methotrexate for 2 weeks after receiving the recombinant herpes zoster vaccine demonstrate improved humoral response, according to data presented at ACR Convergence 2024.
Johnson & Johnson submits sBLAs for Tremfya for two pediatric indications
Johnson & Johnson has submitted two supplemental biologics license applications to the FDA for Tremfya for the treatment of plaque psoriasis and juvenile psoriatic arthritis in children, the company announced in a press release.
FDA approves Yesintek, sixth Stelara biosimilar; launch slated for February
The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.